Ramipril treatment protects against nitrate-induced oxidative stress in eNOS-/- mice: An implication of the NADPH oxidase pathway

Journal of Cardiovascular Pharmacology

Volumn 48, Issue 1, 2006, Pages 842-849

  Otto, Anne ^a   Fontaine, Jeanine ^a   Berkenboom, Guy ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

ACE inhibitors; AT1 antagonist; eNOS knockout mice; NADPH oxidase; NTG tolerance; Oxidative stress

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ACETYLCHOLINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BRADYKININ B2 RECEPTOR ANTAGONIST; CANDESARTAN; COMPLEMENTARY DNA; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCERYL TRINITRATE; ICATIBANT; RAMIPRIL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; CHEMOLUMINESCENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ISCHEMIC HEART DISEASE; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; VASODILATATION;

ACETYLCHOLINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AORTA, THORACIC; BLOOD PRESSURE; BRADYKININ; CYCLIC GMP; FEMALE; INJECTIONS, SUBCUTANEOUS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NADPH OXIDASE; NITRIC OXIDE SYNTHASE TYPE III; NITROGLYCERIN; OXIDATIVE STRESS; RAMIPRIL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASODILATION;

EID: 33747757507     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000238587.68239.52     Document Type: Article

References (32)

1. Abrams J. Mechanisms of action of the organic nitrates in the treatment of myocardial ischemia. Am J Cardiol. 1992;70:30B-42B.
2. Fung HL. Biochemical mechanism of nitroglycerin action and tolerance: is this old mystery solved? Annu Rev Pharmacol Toxicol. 2004;44:67-85.
3. Munzel T, Kurz S, Rajagopalan S, et al. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J Clin Invest. 1996;98:1465-1470.
4. Griendling KK, Minieri CA, Ollerenshaw JD, et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141-1148.
5. Munzel T, Li H, Mollnau H, et al. Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability. Circ Res. 2000;86:E7-E12.
6. Kaesemeyer WH, Ogonowski AA, Jin L, et al. Endothelial nitric oxide synthase is a site of superoxide synthesis in endothelial cells treated with glyceryl trinitrate. Br J Pharmacol. 2000;131:1019-1023.
7. Kurz S, Hink U, Nickenig G, et al. Evidence for a causal role of the renin-angiotensin system in nitrate tolerance. Circulation. 1999;99:3181-3187.
8. Berkenboom G, Fontaine D, Unger P, et al. Absence of nitrate tolerance after long-term treatment with ramipril: an endothelium-dependent mechanism. J Cardiovasc Pharmacol. 1999;34:547-553.
9. Suda O, Tsutsui M, Morishita T, et al. Long-term treatment with N(omega)-nitro-L-arginine methyl ester causes arteriosclerotic coronary lesions in endothelial nitric oxide synthase-deficient mice. Circulation. 2002;106:1729-1735.
10. Marin-Castano ME, Schanstra JP, Neau E, et al. Induction of functional bradykinin b(1)-receptors in normotensive rats and mice under chronic angiotensin-converting enzyme inhibitor treatment. Circulation. 2002;105:627-632.
11. Wagner C, Pfeifer A, Ruth P, et al. Role of cGMP-kinase II in the control of renin secretion and renin expression. J Clin Invest. 1998;102:1576-1582.
12. Wang EQ, Lee WI, Fung HL. Lack of critical involvement of endothelial nitric oxide synthase in vascular nitrate tolerance in mice. Br J Pharmacol. 2002;135:299-302.
13. Hiyoshi H, Yayama K, Takano M, et al. Angiotensin type 2 receptor-mediated phosphorylation of eNOS in the aortas of mice with 2-kidney, 1-clip hypertension. Hypertension. 2005;45:967-973.
14. Taal MW, Chertow GM, Rennke HG, et al. Mechanisms underlying renoprotection during renin-angiotensin system blockade. Am J Physiol Renal Physiol. 2001;280:F343-F355.
15. Levy JV. Prostacyclin-induced contraction of isolated aortic strips from normal and spontaneously hypertensive rats (SHR). Prostaglandins. 1980;19:517-525.
16. Sabetkar M, Naseem KM, Tullett JM, et al. Synergism between nitric oxide and hydrogen peroxide in the inhibition of platelet function: the roles of soluble guanylyl cyclase and vasodilator-stimulated phosphoprotein. Nitric Oxide. 2001;5:233-242.
17. Qian X, Prabhakar S, Nandi A, et al. Expression of GC-C, a receptor-guanylate cyclase, and its endogenous ligands uroguanylin and guanylin along the rostrocaudal axis of the intestine. Endocrinology. 2000;141:3210-3224.
18. Berkenboom G, Brekine D, Unger P, et al. Chronic angiotensin-converting enzyme inhibition and endothelial function of rat aorta. Hypertension. 1995;26:738-743.
19. Wagner AH, Kohler T, Ruckschloss U, et al. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol. 2000;20:61-69.
20. Berkenboom G, Langer I, Carpentier Y, et al. Ramipril prevents endothelial dysfunction induced by oxidized low-density lipoproteins: a bradykinin-dependent mechanism. Hypertension. 1997;30:371-376.
21. Brandes RP, Schmitz-Winnenthal FH, Feletou M, et al. An endothelium-derived hyperpolarizing factor distinct from NO and prostacyclin is a major endothelium-dependent vasodilator in resistance vessels of wild-type and endothelial NO synthase knockout mice. Proc Natl Acad Sci U S A. 2000;97:9747-9752.
22. Chlopicki S, Kozlovski VI, Lorkowska B, et al. Compensation of endothelium-dependent responses in coronary circulation of eNOS-deficient mice. J Cardiovasc Pharmacol. 2005;46:115-123.
23. Laursen JB, Mulsch A, Boesgaard S, et al. In vivo nitrate tolerance is not associated with reduced bioconversion of nitroglycerin to nitric oxide. Circulation. 1996;94:2241-2247.
24. Munzel T, Heitzer T, Brockhoff C. Neurohormonal activation and nitrate tolerance: implications for concomitant therapy with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Am J Cardiol. 1998;81:30A-40A.
25. Mulsch A, Oelze M, Kloss S, et al. Effects of in vivo nitroglycerin treatment on activity and expression of the guanylyl cyclase and cGMP-dependent protein kinase and their downstream target vasodilator-stimulated phosphoprotein in aorta. Circulation. 2001;103:2188-2194.
26. Schulz E, Tsilimingas N, Rinze R, et al. Functional and biochemical analysis of endothelial (dys)function and NO/cGMP signaling in human blood vessels with and without nitroglycerin pretreatment. Circulation. 2002;105:1170-1175.
27. Sydow K, Daiber A, Oelze M, et al. Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J Clin Invest. 2004;113:482-489.
28. Abou-Mohamed G, Kaesemeyer WH, Caldwell RB, et al. Role of L-arginine in the vascular actions and development of tolerance to nitroglycerin. Br J Pharmacol. 2000;130:211-218.
29. Ratz JD, McGuire JJ, Anderson DJ, et al. Effects of the flavoprotein inhibitor, diphenyleneiodonium sulfate, on ex vivo organic nitrate tolerance in the rat. J Pharmacol Exp Ther. 2000;293:569-577.
30. Balazy M, Kaminski PM, Mao K, et al. S-Nitroglutathione, a product of the reaction between peroxynitrite and glutathione that generates nitric oxide. J Biol Chem. 1998;273:32009-32015.
31. Otto A, Fontaine D, Fontaine J, et al. Rosuvastatin treatment protects against nitrate-induced oxidative stress. J Cardiovasc Pharmacol. 2005;46:177-184.
32. Karlsson K, Marklund SL. Extracellular superoxide dismutase in the vascular system of mammals. Biochem J. 1988;255:223-228.